Induction of strong cytotoxic T-lymphocyte responses to hepatitis C virus with recombinant poly-epitope in BALB/c Mice

Viral Immunology

Volumn 19, Issue 1, 2006, Pages 64-73

  Yan, J ^a   Ling, S ^a   Liu, H ^a   Zhang, H ^a   Song, X ^a   Xiu, B ^a   Chen, K ^a   Wang, G ^a   Zhu, C ^a   Ling, Shi Gan ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; HEPATITIS C VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NONSTRUCTURAL PROTEIN 3; RECOMBINANT POLYEPITOPE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSPOT ASSAY; GENETIC TRANSFECTION; HEPATITIS C VIRUS; IMMUNE RESPONSE; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; REVIEW; VACCINATION; VIREMIA; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; FEMALE; HEPACIVIRUS; HEPATITIS C; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA; HEPATITIS C VIRUS;

EID: 33645470204     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.19.64     Document Type: Review

References (61)

1. Giuggio, V.M., H.L. Bonkovsky, and A.L. Rothman. 2005. Evolution of the intrahepatic T cell repertoire during chronic hepatitis C virus infection. Viral Immunol. 18:179-189.
2. Bellentani, S., L. Miglioli, G. Bedogni, et al. 2005. Epidemiology of hepatitis C virus infection. Minerva Gastroenterol. Dietol. 51:15-29.
3. He, X.S., and H.B. Greenberg. 2002. CD8+ T-cell response against hepatitis C virus. Viral Immunol. 15:121-131.
4. Matsui, M., O. Moriya, N. Abdel-Aziz, et al. 2002. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus. Vaccine 21:211-220.
5. Moriya, O., M. Matsui, M. Osorio, et al. 2001. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein. Vaccine 20:789-796.
6. Smith, M.W., Z.N. Yue, M.J. Korth, et al. 2003. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology 38:1458-1467.
7. Rambaut, A., D. Posada, K.A. Crandall, et al. 2004. The causes and consequences of HIV evolution. Nat. Rev. Genet. 5:52-61.
8. Li, Q., C. Dong, J. Wang, et al. 2003. Induction of hepatitis C virus-specific humoral and cellular immune responses in mice and rhesus by artificial multiple epitopes sequence. Viral Immunol. 16:321-333.
9. Braciale, T.J., L.A. Morrison, M.T. Sweetser, et al. 1987. Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol. Rev. 98:95-114.
10. Pamer, E., and P. Cresswell. 1998. Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol. 16:323-358.
11. Jondal, M., R. Schirmbeck, and J. Reimann. 1996. MHC class I-restricted CTL responses to exogenous antigens. Immunity 5:295-302.
12. Carbone, F.R., C. Kurts, S.R. Bennett, et al. 1998. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol. Today 19:368-373.
13. Chikh, G.G., S. Kong, M.B. Bally, et al. 2001. Efficient delivery of antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J. Immunol. 167:6462-6470.
14. Turner, C., N. Weir, C. Catterall, et al. 2002. The transfection of Jurkat T-leukemic cells by use of pH-sensitive immunoliposomes. J. Liposome. Res. 12:45-50.
15. Le, T.T., D. Drane, J. Malliaros, et al. 2001. Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. Vaccine 19:4669-4675.
16. Storni, T., F. Lechner, I. Erdmann, et al. 2002. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J. Immunol. 15;168:2880-2886.
17. Casey, D.G., J. Lysaght, T. James, et al. 2003. Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine. Immunology 110:105-111.
18. Day, F.H., Y. Zhang, P. Clair, et al. 2003. Induction of antigen-specific CTL responses using antigens conjugated to short peptide vectors. J. Immunol. 170:1498-1503.
19. Esumi, M., T. Rikihisa, S. Nishimura, et al. 1999. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees. Arch. Virol. 144:973-980.
20. Cerino, A., A. Meola, L. Segagni, et al. 2001. Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles. J. Immunol. 167:3878-3886.
21. Farci, P., A. Shimoda, D. Wong, et al. 1996. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. U.S.A. 93:15394-15399.
22. Xiu, B.S., S.G. Ling, X.G. Song, et al. 2003. Cross-reactivity of hypervariable region 1 chimera of hepatitis C virus. World J. Gastroenterol. 9:1256-1260.
23. McCluskie, M.J., Y.M. Wen, Q. Di, et al. 1998. Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. Viral Immunol. 11:245-252.
24. Pokric, B., D. Sladic, S. Juros, et al. 1993. Application of the immune complex for immune protection against viral disease. Vaccine 11:655-659.
25. Steinman, RM. 2001. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt. Sinai J. Med. 68:106-166.
26. Berlyn, K.A., N. Schultes, B. Leveugle, et al. 2001. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin. Immunol. 101:276-283.
27. Wen, Y.M., D. Qu, and S.H. Zhou. 1999. Antigen-antibody complex as therapeutic vaccine for viral hepatitis B. Int. Rev. Immunol. 18:251-258.
28. Daeron, M. 1997. Fc receptor biology. Annu. Rev. Immunol. 15:203-234.
29. You, Z.Y., X.F. Huang, J. Hester, et al. 2000. Induction of vigorous helper and cytotoxic T cell as well as B cell response by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway. J. Immunol. 165:4581-4592.
30. Villinger, F., A.E. Mayne, P. Bostic, et al. 2003. Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques. J. Virol. 77:10-24.
31. Song, X.G., S.G. Ling, H.Q. Zhang, et al. 2001. Construction of prokaryotic expression vector (pBVIL1) and using it in the expression of antigens of hepatitis C virus. J. Cell. Mol. Immunol. 17:231-235
32. Lamonaca, V., G. Missale, S. Urbani, et al. 1999. Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: implications for vaccine development. Hepatology 30:1088-1098.
33. Missale, G., R. Bertoni, V. Lamonaca, et al. 1996. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98:706-714.
34. Hoffmann, R.M., H.M. Diepolder, R. Zachoval, et al. 1995. Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology 21:632-638.
35. Lechmann, M., H.G. Ihlenfeldt, I. Braunschweiger, et al. 1996. T-and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology 24:790-795.
36. Roels, G.L., C.A. Esquivel, R. Deleys, et al. 1996. Lymphoproliferative responses to hepatitis C virus core, E1, E2, and NS3 in patients with chronic hepatitis C infection treated with interferon Alfa. Hepatology 23:8-16.
37. Pape, G.R., T.J. Gerlach, H.M. Diepolder, et al. 1999. Role of the specific T cell response for clearance and control of hepatitis C virus. J. Viral. Hepatitis 6(Suppl 1):36-40.
38. Cerny, A., J.G. McHutchison, C. Pasquinelli, et al. 1995. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA-A2.1 binding motif. J. Clin. Invest. 95:521-530.
39. Battegay, M., J. Fikes, A.M.D. Bisceglie, et al. 1995. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J. Virol. 69:2462-2470.
40. Shirai, M., T. Arichi, M. Nishioka, et al. 1995. CTL response of HLA-A2.1-transgenic mice specific for hepatitis C virus peptides predict epitopes for CTL of humans carrying HLA-A2.1. J. Immunol. 154:2733-2742.
41. Shirai, M., H. Okada, M. Nishioka, et al. 1994. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J. Virol. 68:334-342.
42. Lechner, F., K.H. Wong, P.R. Dunbar, et al. 2000. Analysis of successful Immune reponses in persons infected with hepatitis C virus. J. Exp. Med. 191:1499-1512.
43. Lee, A.Y., N.K. Polakos, G.R. Otten, et al. 2000. Quantification of the number of cytotoxic T cells specific for an immunodominant HCV-specific CTL epitope primed by DNA immunization. Vaccine 18:1962-1968.
44. Kita, H., K. Hiroishi, T. Moriyama, et al. 1995. A minimal and optimal cytotoxic T cell epitope within hepatitis C virus nucleoprotein. J. Gen. Virol. 76:3189-3193.
45. Chang, K.M., N.H. Gruener, S. Southwood, et al. 1999. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J. Immunol. 162:1156-1164.
46. Ibe, M., T. Sakaguchi, K. Tanaka, et al. 1998. Identification and characterization of a cytotoxic T cell epitope of hepatitis C virus presented by HLA-B*3501 in acute hepatitis. J. Gen. Virol. 79:1735-1744.
47. Kurokohchi, K., K. Arima, M. Nishioka, et al. 2001. A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection. J. Hepatol. 34:930-935.
48. Rammensee, H.G., T. Friede, and S. Stevanoviic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178-228.
49. Woodberry, T., J. Gardner, L. Mateo, et al. 1999. Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes. J. Virol. 73:5320-5325.
50. Mateo, L., J. Gardner, Q. Chen, et al. 1999. An HLA-A2 polyepitope vaccine for melanoma immunotherapy. J. Immunol. 163:4058-4063.
51. Thomson S.A., R. Khanna, J. Gardner, et al. 1995. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells:implications for vaccine design. Proc. Natl. Acad. Sci. U.S.A. 92:5845-5849.
52. Grakoui, A., N.H. Shoukry, D.J. Woollard, et al. 2003. HCV persistence and immune evasion in the absence of memory T cell help. Science 302:659-662.
53. Gerlach, J.T., H.M. Diepolder, M.C. Jung, et al. 1999. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117:933-941.
54. Zhu, F., D.D. Eckels. 2002. Functionally distinct helper T-cell epitopes of HCV and their role in modulation of NS3-specific, CD8+/tetramer positive CTL. Hum. Immunol. 63:710-718.
55. Wang, J.H., T.J. Layden, and D.D. Eckels. 2003. Modulation of the peripheral T-Cell response by CD4 mutants of hepatitis C virus: transition from a Th1 to a Th2 response. Hum. Immunol. 64:662-673.
56. Chang, J.S., M.J. Choi, H.S. Cheong, et al. 2001. Development of Th1-mediated CD8+ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes. Vaccine 19:3608-3614.
57. Godkin, A.J., K.J. Smith, A. Willis, et al. 2001. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions. J. Immunol. 166:6720-6727.
58. Shimbara, N., K. Ogawa, Y. Hidaka, et al. 1998. Contribution of proline residue for efficient production of MHC class I ligands by proteasomes. J. Biol. Chem. 273: 23062-23071.
59. Shastri, N., T. Serwold, and F. Gonzalez. 1995. Presentation of endogenous peptide/MHC class I complexes is profoundly influenced by specific C-terminal flanking residues. J. Immunol. 155:4339-4346.
60. Bergmann, C.C., Q. Yao, C.K. Ho, et al. 1996. Flanking residues alter antigenicity and immunogenicity of multiunit CTL epitopes. J. Immunol. 157:3242-3249.
61. Livingston, B.D., M. Newman, C. Crimi, et al. 2001. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19: 4652-4660.